Utilizing Pharmacogenomics Results to Guide Antidepressant Selection: A Case Report.

Nicholas Vernacchia¹, Nicole Del Toro-Pagán¹, Chandni Bardolia¹, Nishita Shah Amin¹

¹1 Office of Translational Research and Residency Programs, Tabula Rasa HealthCare, Moorestown, New Jersey.

Abstract

The case discussion demonstrates the benefit of using Pharmacogenomic (PGx) results to aid in the selection of antidepressant therapy and improve response to treatment. Nearly half of patients diagnosed with major depressive disorder fail initial therapy and may require multiple trials of antidepressants. Genetic variation in several metabolic enzymes contribute to the variable response to antidep…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.